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So-called energy shots are a new kind of energy drinks that contain caffeine and taurine. In 
advertisements, these are claimed to increase concentration and capacity or physical per-
formance. They are marketed in smaller portions (25-75 ml) than the more common energy 
drinks yet contain a higher concentration of caffeine and in some cases taurine per litre than 
energy drinks. The compositions of energy shots known to BfR vary significantly and contain 
between 50-200 mg caffeine and 200-1000 mg taurine per portion. In contrast to energy 
drinks, these energy shots are labelled with the manufacturer’s suggested intake levels. All of 
those known to BfR thus far uniformly recommend one portion per day. 
 
In BfR’s opinion, energy shots that contain the constituents listed above pose no health risk if 
consumed in accordance with the manufacturer’s intended use, i.e. one portion per day, and 
other product labels. 
 
Health risks can result if the suggested intake level is exceeded considerably. This could 
mean that the constituents (caffeine and taurine) are consumed in considerably higher 
amounts and/or over a shorter time span than before with ordinary energy drinks. Yet the 
potential extent should be estimated differently due to varying amounts of caffeine and 
taurine in individual energy shots. Excessive doses of caffeine can lead to risks associated 
with known potential adverse effects. It remains to be clarified whether the interaction of caf-
feine with other constituents in energy drinks (e.g. taurine) or with ethanol in the alcoholic 
beverages consumed alongside energy shots or with physical exertion (e.g. extended, physi-
cally strenuous dancing or sports activities) could amplify the adverse effects of caffeine. An 
actual causal relationship between these factors has not yet been scientifically demon-
strated. The extent of potential health risks depends on the intake amounts (caffeine and 
taurine) and the manner of intake (e.g. once, rapid intake over a short period of time, high 
amounts distributed over several single doses), on individual consumer sensitivity to the ef-
fects of caffeine, the usual amount of caffeine consumed daily, the amount of caffeine con-
sumed through other sources of caffeine as well as potential parallel factors such as alcohol 
intake or strenuous physical/sports activity.  
 
According to BfR, there is a risk that energy shots are not used in accordance with the manu-
facturer’s advice for intended use. The Institute assumes that energy shots are sometimes 
consumed in place of energy drinks and thus consumed – like these – at the discretion of the 
consumer without quantitative limit. It should also be noted that consumers in night clubs 
may choose to increase their energy shot intake in an attempt to counteract fatigue or to 
reach a state of arousal. Since physical exertion also increases thirst, there is a risk that the 
suggested intake levels of energy shots are not adhered to. 
 
According to BfR, the desire to improve performance produces a risk of excessive energy 
shot intake. As consumers can be expected to disregard the advice for intended use, thus 
taking in high doses of caffeine which could result in adverse effects, the Institute deems 
energy shots unsafe. BfR estimates that such expected consumer behaviour cannot be pre-
vented by the manufacturer’s advice for intended use.  
 
1   Subject of the assessment  
In Germany, so-called “energy shots” are to be marketed or are currently marketed as dietary 
supplements. Energy shots are similar to energy drinks in composition and appearance. En-
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ergy drinks are non-alcoholic beverages that contain high amounts of caffeine and taurine 
and sometimes glucuronolactone and inositol. However, the concentration of caffeine and 
taurine in energy shots far exceeds the amounts allowed in energy drinks. The Federal Min-
istry of Food, Agriculture and Consumer Protection (BMELV) has asked the Federal Institute 
for Risk Assessment (BfR) to issue an opinion on the consumer health risk of these products. 
 
At the time of the assessment, seven energy shots are known to BfR. Five of these products 
are labelled as dietary supplements. One product is labelled a dietetic dietary supplement for 
intense muscular exertion, especially for athletes. One other product is also intended for ath-
letes.  
 
The caffeine concentration in these products is 1.3-6 g/L, the taurine concentration is  
4-20 g/L and portion volumes are 25-75 ml. Present information indicates that all products 
carry the manufacturer’s advice for intended use, which uniformly state one portion per day. 
If used accordingly, caffeine intake is 50-200 mg/day and taurine intake is 200-1000 mg/day 
depending on each product. In six of the products, the caffeine concentration is provided 
exclusively by caffeine, in one product it is provided exclusively by guarana extract. Some of 
the products contain added inositol (up to 50 mg/portion) and two products have added glu-
curonolactone (70 mg/portion), while one product contains no information on the amounts 
added.  
 
With the exception of one product, the labels indicate increased caffeine concentration and 
one product (200 mg caffeine/portion) carries the notice “high caffeine concentration”. Five 
products also carry (warning) labels stating that they are not suitable for children, pregnant 
women and caffeine-sensitive individuals, and in some cases additional groups (breast-
feeding mothers, diabetics) are named. One product (200 mg caffeine/portion) is labelled 
unsuitable for individuals with high blood pressure and cardiovascular disease in addition to 
children and pregnant and breast-feeding women. 
 
2   Results 
The compositions of energy shots assessed here vary significantly (caffeine concentrations 
1.3-6 g/L, taurine concentrations 4-20 g/L). With respect to the manufacturer’s advice for 
intended use (1 portion/day), caffeine intake ranges from 50-200 mg and taurine intake 
ranges from 200-1000 mg/day. 
 
Consumer health can be at risk if the intake of the energy shots in question considerably 
exceeds the amount indicated on the label. In this case, the constituents (caffeine and 
taurine) may be consumed in much higher doses and/or over shorter periods of time than 
those of energy drinks have been, and the potential extent differs due to the varying caffeine 
and taurine concentrations of individual energy shots. Potential adverse effects commonly 
associated with excess caffeine intake can thus lead to risks. Furthermore, it is suspected 
that the interaction of caffeine with other constituents in energy drinks (e.g. taurine) or with 
ethanol in the alcoholic beverages consumed together with energy shots or with physical 
exertion (e.g. extended, physically strenuous dancing) or sports activities could amplify the 
adverse effects of caffeine. The extent of potential health risks depends on the intake 
amounts as well as the time span in which these occur (boluses, rapid intake over a time 
span, distribution of high intake amounts over several single doses and several hours), on 
individual consumer sensitivity to the effects of caffeine, the usual amount of caffeine con-
sumed daily, the amount of caffeine consumed through other sources as well as potential 
parallel factors such as alcohol intake or strenuous physical/sports activity. 
 
  Page 2 of 14 
 Federal Institute for Risk Assessment 
According to BfR, there is a risk that energy shots are not used in accordance with the manu-
facturer’s advice for intended use. As consumers can be expected to disregard the sug-
gested intake levels, thus taking in high doses of caffeine which could result in adverse ef-
fects, the Institute deems energy shots unsafe in terms of Article 14(1) of Regulation (EC) No 
178/20021. BfR estimates that in the case of “energy shot” products such expected con-
sumer behaviour cannot be prevented by the manufacturer’s advice for intended use on the 
label. BfR therefore recommends that “energy shot” products are prohibited from being 
placed on the market. 
 
3   Reasons 
The following points are important for the health assessment of these products: 
 
3.1   Caffeine  
 
Due to its pharmacological effect, caffeine is on the one hand used for medical purposes (to 
temporarily counteract symptoms of fatigue; BGA, 1988; pharmaceutical product information 
of a caffeine monopreparation, 2008). On the other hand, the use of caffeine in the produc-
tion of common stimulant beverages (e.g. cola, coffee and tea) is widely accepted. However, 
BfR is critical of the use of caffeine in foods consumed in the form of concentrates and not 
consumed in the context of common foods (e.g. in the form of stimulant beverages). This 
form of caffeine intake does not allow consumers to anticipate their potency based on taste 
as traditional stimulant beverages do. 
 
3.1.1   Hazard potential 
 
Caffeine stimulates the central nervous system and can affect the vegetative nervous system 
depending on dose. The effect of caffeine and its metabolites on these organ systems occurs 
through different mechanisms such as the inhibition of adenosine receptors which is espe-
cially essential for a psycho-stimulating, centrally stimulating effect, and other mechanisms 
including the inhibition of phosphodiesterase, increased calcium mobilisation and the an-
tagonistic effect on benzodiazepine receptors (IOM, 2008). 
 
The psycho-stimulating effect on the central nervous system is the main desired effect of 
caffeine, for which a customary single dose of 50-100 mg up to 200 mg is used (Martindale, 
2009). 
 
Acute adverse effects resulting from caffeine intake depend on individual sensitivity and the 
extent of the daily intake of caffeine-containing beverages. Long-term consumption of caf-
feine, especially in medium and higher doses, can lead to the development of a tolerance to 
most of its effects and side effects (BGA, 1988; pharmaceutical product information of a caf-
feine monopreparation, 2008). However, it is known that chronic high caffeine intake can also 
lead to adverse effects (Medsafe Editorial Team, 1999; Greden, 1974; Myerson et al., 2002). 
 
The adverse effects of caffeine in adults include nervousness, irritability, insomnia, nausea, 
headache, tremor, increased anxiety, perceptual disturbances, diuresis, arrhythmia, tachy-
cardia, increased respiration rate and gastrointestinal disturbances (Nawrot et al., 2003; 
Wechsler, 2005). Individual cases of serious poisoning with worse symptoms, such as confu-
sional states after high intake amounts have been reported, though the tablets that were 
                                                
1 Regulation (EC) No 178/2002 of the European Parliament and of the Council laying down the general principles and  
requirements of food law, establishing the European Food Safety Authority and laying down procedures in matters of food 
safety 
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taken also contained high amounts of ammonium chloride (Shaul et al., 1984). A similar 
case, in which caffeine in the gram range had been consumed during two previous days, 
reports a “grand mal” seizure and increased serum creatine kinase levels in connection with 
physical exercise (FitzSimmons and Kidner, 1998). Fatal cases after high caffeine intake 
have also been reported (e.g. Dimaio and Garriott, 1974; Alstott, 1973). 
 
The following information is available on the use of caffeine as pharmaceutical product: 
¾ For the indication “to temporarily counteract symptoms of fatigue”, single doses of 
100 to 200 mg caffeine are used, which can be repeated if necessary, but not 
more than twice within 24 hours (BGA, 1988; pharmaceutical product information 
of a caffeine monopreparation, 2008). 
¾ With regard to “side effects”, the information states that the appearance of side ef-
fects depends on the above named factors and that even low doses (this probably 
refers to 100 mg) can cause tachycardia, insomnia, apprehension and gastroin-
testinal disturbances, while doses over 200 mg can cause irritability, headaches 
and intensified physiological muscle tremors even in individuals with low sensitiv-
ity (pharmaceutical product information of a caffeine monopreparation, 2008). 
¾ In section “special warnings and special precautions for use” patients with hyper-
thyroidism (may increase) and patients with cirrhosis of the liver (caffeine may ac-
cumulate) are advised to take caffeine at a low dosage (about 100 mg) and only 
under medical supervision (pharmaceutical product information of a caffeine mo-
nopreparation, 2008). 
¾ “Overdosing” contains the information that symptoms of poisoning can occur at 1g 
caffeine and more if the amount is taken in a short time span. It also states that fa-
tal doses of caffeine range from 3 g2 and 10 g (pharmaceutical product informa-
tion of a caffeine monopreparation, 2008). 
 
However, individual data and specifications on the use of caffeine as a pharmaceutical prod-
uct from the information cited above (BGA, 1988; pharmaceutical product information of a 
caffeine monopreparation, 2008) are not available to BfR.  
 
Available research publications provide examples of adverse effects ranging from nausea 
and mild tremors to increased anxiety, nervousness, drowsiness and headaches. These 
symptoms occur in single doses ranging from 5 mg/kg body weight (BW) (equivalent to 300 
mg at 60 kg BW) to 700 mg caffeine or when 3 x 300 mg caffeine/day is administered 
(Bender et al., 1997; Bonati et al., 1982; Evans and Griffiths, 1992; Kaplan et al., 1997; 
Charney et al., 1984; Mattila et al., 1988). As a result of the study design (sometimes coffee 
was eliminated before begin of the study), the validity of cited examples is limited.  
The list of documents indicates that adverse effects of caffeine were observed after higher 
caffeine boluses. Yet these do not represent a systematic literature evaluation concerning 
the symptoms of acute adverse caffeine effects or thereby relevant doses. Published, sys-
tematic evaluations on this research question are not available to BfR at present. Further-
more, pharmacovigilance surveillance data of pharmaceutical products relevant to this are 
not publicly available. In addition, available data on acute adverse effects of caffeine admin-
istered in several single doses over a period of several hours are insufficient to derive a 
dose-response relationship. 
 
The potential risks of specific groups (e.g. individuals with cardiovascular diseases or epi-
lepsy) are referred to in Chapter 3.3. 
 
                                                
2 It is unclear whether this dose should apply to adults or children. 
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In reference to the potential risk group of diabetics, it must be noted that in type II diabetes, 
the intake of 250 mg and 375 mg caffeine in conjunction with a subsequent meal led to an 
adverse increase of postprandial hyperglycaemia and postprandial release of insulin (Lane et 
al., 2004; 2007). On the other hand, in type I diabetes, the awareness of signs of hypogly-
caemia was observed to have improved after the intake of 250 mg caffeine (Debrah et al., 
1996). 
 
With regard to children, the Scientific Committee on Food (SCF, 1999) has determined that 
several studies show that the intake of 5 mg caffeine/kg BW increases arousal, irritability, 
nervousness and anxiety in several children, especially if they usually only consume low 
amounts of caffeine. SCF concluded that for children who usually do not consume much tea 
or coffee, the intake of 160 mg caffeine/day in a ten-year-old child weighing 30 kg, equivalent 
to a dose of 5.3 mg caffeine/kg body weight/day, can cause temporary side effects such as 
irritability, nervousness or anxiety (SCF, 1999). 
 
Regarding the special risks of pregnant women, the British Committee on Toxicity of Chemi-
cals in Food, Consumer Products and the Environment (COT, 2008) has evaluated the in-
take of caffeine during pregnancy on the basis of a recent epidemiological study and the 
evaluation of published research studies. The Committee concluded that caffeine intake dur-
ing pregnancy is associated with an increased risk of reduced foetal growth. The Committee 
assumed a causal relationship, yet this could not be substantiated definitively. COT was un-
able to identify a threshold dose, below which there would be no increased risk. However, it 
is probable that intake levels around 200 mg caffeine per day or even less are related to in-
creased risk. Existing research literature indicates that caffeine intake and the occurrence of 
miscarriages are related, though uncertainties in this regard have not been dispelled (COT, 
2008). As a result, the British Food Standards Agency recommended that pregnant women 
should limit their caffeine intake to less than 200 mg/day (FSA, 2008). 
 
Concerning breastfed babies, the biological half-life of caffeine in infants during their first 
months is 65-100 h and considerably higher than that of adults. Caffeine passes into the 
mother’s milk. While the infant is still breastfed, its condition and behaviour can be impaired 
by caffeine taken in along with breast milk (BGA, 1988; pharmaceutical product information 
of a caffeine monopreparation, 2008). Pharmaceutical recommendations state that if the use 




In compliance with the manufacturer’s advice for intended use of these products, the daily 
intake of caffeine is between 50-200 mg.  
 
The caffeine concentration in normal portions of coffee varies depending on preparation, 
portion size and coffee variety. In Germany, one cup of coffee (up to 125 ml) contains be-
tween 50-130 mg caffeine (400-1000 mg/L) (Unknown, 2008). For commonly available larger 
coffee cups (about 200 ml) this would result in caffeine intake between 80-200 mg caf-
feine/portion. In Great Britain, mean values of 105 mg caffeine were determined for portions 
of coffee, while these ranged extremely between 15-254 mg (FSA, 2004). 
 
3.2 Taurine 
The Panel on Food Additives and Nutrient Sources added to Food of the European Food 
Safety Agency (EFSA) has evaluated the use of taurine as constituent in energy drinks. 
EFSA concluded that the daily intake of up to 1400 mg taurine/day is no cause for health 
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concern. A NOAEL (no observed adverse effect level) for rats of at least 1000 mg/kg BW/day 
was assumed in this regard. The EFSA Panel evaluated taurine as single substance, but did 
not take interactions between caffeine and taurine into account, aside from diuretic effects 
that were considered improbable. The Panel did not evaluate the safety of energy drinks as 
such (EFSA, 2009). 
 
In compliance with the manufacturer’s advice for intended use of these products, the daily 
intake of taurine is between 200-1000 mg.  
 
3.3   Combined intake of large amounts of caffeine and taurine in conjunction with the simul-
taneous intake of alcohol and/or sports activity 
In evaluating the health risks of energy drinks or products that have large amounts of caf-
feine and taurine added, it is important to consider the effects of potential interactions. The 
adverse effects of caffeine (cardiovascular system, central nervous system, reproductive 
toxicity) could be amplified when these constituents interact with other energy drink constitu-
ents (e.g. taurine) or ethanol in the alcoholic beverages consumed together with energy 
shots. Furthermore, these effects could also be amplified if energy shots are consumed in 
conjunction with physical exertion or sports activities. In this respect, certain potential risk 
groups such as consumers with cardiovascular disease, epileptics, pregnant women and 
children must be examined separately. As depicted in BfR Opinion “New human data for the 
assessment of energy drinks” (BfR, 2008), current data are not sufficient for a comprehen-
sive evaluation of potential health risks. The additional (warning) labels and recommenda-
tions for certain groups of consumers recommended in this Opinion remain relevant.  
While the literature on this subject reports cardiovascular or other effects and complications, 
even unexplained deaths, after the increased intake of energy drinks usually in conjunction 
with sports activity, physical exertion and/or alcohol intake, causal relationships remain un-
certain (e.g. SCF, 2003; Stimulant Drinks Committee, 2003; Lehtihet, 2006; BfR, 2008). This 
lack of a definitive causal relationship is the basis of ambiguities pertaining to the risk as-
sessment of energy drinks described above. 
The following depicts a short exemplary compilation of such reports, including reports in ref-
erence to potential risk groups listed above as well as a compilation of several clinical stud-
ies. 
 
3.3.1   Case studies 
¾ Case of a 23-year-old man in Greece in 2001 who suffered from a myocardial infarc-
tion after playing football while consuming energy drinks (SCF, 2003). A causal rela-
tionship is uncertain. 
¾ Case of an 18-year-old man who presumably consumed up to 3 cans of an energy 
drink during a basketball tournament in Ireland and suddenly died, presumably as a 
result of cardiac arrhythmia (Stimulant Drinks Committee, 2003). A causal relationship 
is uncertain. 
¾ Case of a 19-year-old woman who consumed about 6 drinks in one evening, which 
contained an energy drink (caffeine concentration 320 mg/L, taurine concentration 4 
g/L) and vodka. Around 7 p.m., she consumed a meal. After midnight, she had not 
consumed any more food or drink and was not very intoxicated. She was found dead 
in her bed the following morning. The forensic medical examination revealed a blood 
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alcohol level of 0.87. A definitive cause of death could not be determined (Lehtihet et 
al., 2006; BfR, 2008). 
¾ Case of a 31-year-old woman in 2001 who consumed drinks containing vodka and 
energy drinks (caffeine concentration 320 mg/L, taurine concentration 4g/L) over the 
course of a dance event. She collapsed during a dance and died in hospital. The fo-
rensic medical examination merely revealed a slight deposit of connective tissue in 
the cardiac muscle and a slight fatty liver. A definitive cause of death could not be de-
termined (Lehtihet et al., 2006; BfR, 2008). 
¾ Case of an 18-year-old man who consumed several cans of an energy drink (caffeine 
concentration 320 mg/L, taurine concentration 4 g/L) a day “in order to remain con-
centrated” and collapsed dead while watching television. The blood ethanol level in 
his thigh was 0.59, in his urine 0.80. The forensic medical examination revealed a 
moderate isolated deposit of connective tissue in the cardiac muscle. A definitive 
cause of death could not be determined (Lehtihet et al., 2006; BfR, 2008). 
¾ Case of a 31-year-old football referee who practiced football on a regular basis. One 
week after participating in a 3000 m match, before which he had consumed three 
cans of an energy drink (caffeine concentration 320 mg/L, taurine concentration 4 
g/L), he was diagnosed with rhabdomyolysis and acute kidney failure with tubular ne-
crosis of uncertain cause (Lehtihet et al., 2006; BfR, 2008). 
¾ Case of a 28-year-old motocross race driver who suffered from cardiac arrest during 
a motocross racing tournament, but survived following treatment. He had consumed 
7-8 cans of an energy drink (caffeine concentration 80 mg/can) within 7 hours. The 
cause of the incident could not be determined. The authors presume that the exces-
sive intake of energy drinks and strenuous physical activity could trigger potentially fa-
tal myocardial ischaemia in predisposed individuals (Berger and Alford, 2009). 
¾ In January and February 2008, BfR enquired at the Federal Office of Consumer Pro-
tection and Food Safety (BVL) and the German poison information centres (GIZs) on 
reports concerning health detriments following the intake of energy drinks. BVL had 
no such reports since 2005. 6 of the total 9 GIZs of the Federal Republic of Germany 
had information according to which a total of 91 reports (double-counting possible) of 
adverse effects following the intake of energy drinks emerged between 2001 and 
2007 (partly shorter recording periods of individual GIZs). These effects were some-
times observed to occur following very high intake amounts of energy drinks and/or in 
combination with the consumption of alcoholic beverages, pharmaceutical products or 
drugs. Due to the recapitulating portrayal of events which lack critical details, a causal 
relationship can not be derived. This also applies to the death of a young adult who 
died before the emergency physician arrived, after he had consumed unknown 
amounts of energy drinks with vodka at a party. The symptoms that have been de-
scribed include stomach aches, high blood pressure, tachycardia (accelerated heart 
rate), ventricular fibrillation, impaired vision, convulsions and myoclonus (muscle 
spasms). 
¾ The sudden death of a young woman possibly related to the intake of a product re-
ferred to as “energy blast” that contained guarana and ginseng. The woman suffered 
from a mitral valve prolapse. The caffeine concentration of the beverage was 10 g/L; 
the portion size was 55 ml equivalent to a caffeine intake of 550 mg/portion (Cannon 
et al., 2001). The authors state that the woman received a bottle of the product and 
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nearly emptied it, while the Australian Adverse Drug Reactions Advisory Committee 
states that the intake amount is unknown (ADRAC, 2000). No additional information 
on product composition and ingredients that could be relevant is available. The re-
ports state that in general the young woman did not consume great amounts of cof-
fee. The effect of caffeine was regarded as a likely factor to have contributed to her 
death (ADRAC, 2000). 
¾ Two cases of tachycardia (in one case associated with orthostatic intolerance) that 
were observed in connection with the consumption of energy drinks, i.e. of a bever-
age referred to as “speed shots”, which contained additional plant extracts besides 
caffeine (Nagajothi et al., 2009; Terlizzi et al., 2008) (see also EFSA evaluation below 
of Iyadurai and Chung, 2007). 
¾ Case of an adult who consumed up to eight cups of espresso and an additional 6 
cans of an energy drink (caffeine concentration 320 mg/L, taurine concentration 4 g/L) 
per day (estimated total intake of 1.3 g caffeine/day) over the course of several 
months and developed arrhythmia with atrial fibrillation (Myerson et al., 2002). It is 
known that chronic high intake levels of caffeine can induce arrhythmia (Greden, 
1974). 
¾ Iyadurai and Chung (2007) describe four patients who experienced generalised cere-
bral convulsions following the intake of energy drinks in high doses but not in low 
doses without the reported simultaneous intake of alcohol. For example, a healthy 25-
year-old man twice experienced generalised cerebral convulsions with a four-month 
interval after consuming energy drinks in a fasted state. He had neither suffered from 
such a symptom previously, nor did it recur after a six-month abstinence from energy 
drinks. At his last exposure, he had consumed 1420 ml (2 x 24 ounces) of an energy 
drink 30 to 60 minutes prior to the convulsions. Two other patients who experienced 
convulsions after energy drink intake, generally suffered from migraine headaches, 
and in one case the energy drink was consumed in a fasted state, in the other case it 
was accompanied by the intake of pills that contained large amounts of caffeine. A 
fourth patient, who suffered convulsions for the fourth time, was cited to state that he 
only experienced convulsions after consuming more than 1420 ml of an energy drink. 
The authors state that none of the patients had additional convulsions after abstaining 
from energy drinks and previously only had convulsions after the intake of higher 
amounts. Neurological clarifications provided no indications for other causes. The caf-
feine and taurine levels in the energy drinks are not known. The products contained 
additional plant extracts such as guarana, ginseng, ginkgo or milk thistle. In its Scien-
tific Opinion on taurine and glucuronolactone, EFSA (2009) stated the possibility that 
these effects as well as those described by Nagajothi et al. and Terlizzi et al. (see 
above) could be due to the known side effects of caffeine, and that there is no scien-
tific evidence to suggest a causal relationship with the intake of taurine. On the other 
hand, the Panel stated that interactions between caffeine and taurine, aside from diu-
retic effects, have not been studied. It is known that high doses of caffeine can induce 
convulsions and lower the limit of the occurrence of convulsions in epilepsy patients. 
 
3.3.2   Human study 
Furthermore, though due to their design and small number of participants they can only 
serve as orientation, findings from human studies indicate possible cardiovascular risks that 
could become relevant in conjunction with physical exertion: 
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¾ 10 participants (aged 19-30 years) 30 minutes prior to maximum physical stress on a 
bicycle ergometer received a) nothing to drink, b) 750 ml of an energy drink (240 mg 
caffeine, 3000 mg taurine), c) 750 ml of an energy drink plus 0.4 g alcohol/kg BW and 
d) 750 ml of an energy drink without subsequent physical stress. In conclusion, the 
comparison of group c) with group a) revealed delayed pulse rate recovery after 
physical stress. A lowered heart rate variability (HRV) is regarded to indicate a re-
duced balance of the autonomic nervous system and is correlated with an increased 
risk of arrhythmia, which in turn is considered to increase the risk of sudden cardiac 
death. Furthermore, low-grade electrocardiogram (ECG) changes in groups b) and c) 
were registered before the stress test. One participant developed temporary prema-
ture atrial systole after energy drink intake, but not after simultaneous alcohol intake. 
The authors state that no clinically significant arrhythmia was observed. They do 
however hypothesise that under similar conditions (intake of energy drinks with alco-
hol in conjunction with physical exertion) individuals who are predisposed for ar-
rhythmia could have an increased risk of arrhythmia (Wiklund et al., 2009). 
¾ In an exploratory study Steinke et al. (2009) examined the cardiovascular effects of 
energy drinks in 15 healthy participants (average age 26 years) with low blood pres-
sure at physical rest. After an initial examination during which blood pressure and 
heart rate were taken and an ECG was determined, each participant consumed 500 
ml of an energy drink (2 cans), which contained a total of 160 mg caffeine and 200 
mg taurine, within 30 minutes. The examinations were repeated after 30 minutes, 
one, two, three and four hours. Over the next five days, each participant consumed 
500 ml/day, and on the seventh day, the procedure of the first day was repeated. On 
both days, four hours after the energy drink had been consumed, a raised mean sys-
tolic blood pressure by 9-10 mm Hg and an increased heart rate by 5-7 beats per 
minute were determined. Habituation after several days of intake was not observed. 
Over the course of the study, seven participants reported adverse effects such as 
“flightiness”, gastrointestinal symptoms, urinary urgency or insomnia, though it should 
be noted that the participants usually only consumed low doses of caffeine and the 
study did not include a control group. Until further findings are available, Steinke et al. 
urged patients with cardiovascular diseases to abstain from energy drink consump-
tion. 
 
3.4   Risk characterisation  
The energy shots available are of very heterogeneous composition. Their caffeine concentra-
tion varies between 50-200 mg/portion and their taurine concentration is between 200-1000 
mg/portion. 
 
3.4.1   Use in accordance with the requirements 
 
If a use in accordance with the suggested intake levels is presupposed, products could 
pragmatically be divided into the following two groups (see 3.4.1.1 and 3.4.1.2). 
 
3.4.1.1   Products with a caffeine concentration that clearly exceeds the concentration of pre-
viously regular 250 ml portion energy drinks (150-200 mg caffeine/portion, taurine concentra-
tion up to 1000 mg/portion) (category A energy shot) 
The following points are essential with regard to these products: 
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¾ Pregnant women are advised to consume not more than 200 mg caffeine/day. Prod-
ucts that contain 150 mg caffeine/portion also constitute a very high intake level in 
this context. BfR recommends that such products are labelled as unsuitable for preg-
nant women. 
¾ Since infants could be affected negatively by caffeine intake along with breast milk, 
BfR recommends that such products are labelled as unsuitable for breast-feeding 
mothers. 
¾ With portions of 150 mg children (10 years old, 30 kg BW; SCF, 1999) reach intake 
levels of 5 mg caffeine/kg BW. These have been connected with the temporary ap-
pearance of arousal, irritability, nervousness and anxiety in several children (SCF, 
1999). These products should therefore be labelled as unsuitable for children. 
¾ In light of the information presented in Chapter 3.3, BfR recommends that the afore-
mentioned products are labelled as unsuitable for caffeine-sensitive individuals until 
clarifying studies are available. It should be noted that patients with arrhythmia or 
mental illnesses, possibly also individuals with heart diseases other than arrhythmia 
should be considered to belong to the group of caffeine-sensitive individuals. They 
should therefore be considered as a risk group that potentially reacts very sensitively 
to the effects of energy drinks. 
¾ BfR recommends that product labels contain adequate notices concerning the in-
creased caffeine concentration and actual caffeine concentration per portion of these 
products. 
¾ Since these products might also be consumed in combination with regular energy 
drinks, BfR recommends that the notice recommended for energy drinks “if larger 
amounts of such drinks (i.e. energy drinks and energy shots) are consumed in con-
junction with extensive sports activity or the intake of alcoholic beverages, adverse ef-
fects can not be excluded” is adequately adopted. 
 
3.4.1.2   Products with a caffeine and/or taurine concentration that is in the range of previ-
ously regular 250 ml portions of energy drinks (caffeine concentration rounded to 100 
mg/portion; taurine concentration up to 1000 mg/portion) (category B energy shots) 
If they are used in accordance with the manufacturer’s advice for intended use, this category 
of energy shots raises no health concerns in light of the fact that the caffeine and taurine 
intake levels correspond to those of regular energy drink portions, energy drinks are lawfully 
marketed and these products are ordinarily consumed as desired. However, the products are 
significant sources of caffeine. BfR recommends that a label indicates the increased caffeine 
concentration per portion of these products. 
Since these products are also sometimes consumed in combination with regular energy 
drinks, BfR recommends a second label in addition to the above mentioned notice informing 
that “in particular larger amounts of such drinks (i.e. energy drinks and energy shots) are not 
recommended for children, pregnant and breastfeeding women and caffeine-sensitive indi-
viduals“. 
 
3.4.2   Predictable use not in accordance with the requirements 
Furthermore, health risks can result if the energy shots under consideration are not con-
sumed in accordance with the manufacturer’s advice for intended use and considerably ex-
ceed suggested intake levels. It appears realistic that some consumers do not consume en-
ergy shots in accordance with the manufacturer’s advice, but in part as a substitute for en-
ergy drinks and – like these – consume energy shots at personal discretion without quantita-
tive limit. This occurs in part because of the fact that energy drinks and their constituents are 
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advertised positively but also because consumers cannot judge the potency of this form of 
caffeine intake through its taste as it is possible for the traditional stimulant beverages coffee 
and tea.  
 
As a result of the concentrated form with considerably higher caffeine concentrations (1.36-6 
g/L in contrast to 0.32 g/L) and sometimes taurine concentrations (4-20 g/L in contrast to 4 
g/L), a volume effect contributing to naturally constrained consumption of energy drinks and 
their constituents does not apply to energy shots. This facilitates the intake of higher 
amounts of caffeine and taurine over a shorter time span than by use of former energy 
drinks. However, the potential extent must be estimated variably due to different caffeine and 
taurine concentrations in the energy shots mentioned. The health risks resulting from such 
intake behaviour have not been adequately researched and there are considerable informa-
tion gaps. Health risks depend on the intake amounts as well as the time span in which these 
occur (boluses, rapid intake over a short period of time, distribution of high intake amounts 
over several single doses and several hours), on individual consumer sensitivity to the ef-
fects of caffeine, the usual amount of caffeine consumed daily, the amount of caffeine con-
sumed through other sources of caffeine as well as potential parallel factors such as alcohol 
intake or strenuous physical/sports activity. 
 
If the suggested intake levels of energy shots are exceeded considerably, the excessive caf-
feine intake amounts can lead to health risks. However, at present, health risks related to 
intake amounts cannot be accurately determined especially in regard to the distribution over 
several single doses over an extended period during a day, particularly because consumer-
specific factors mentioned above are also relevant. Furthermore, though the circumstances 
are uncertain, it is suspected that the adverse effects of caffeine (cardiovascular and central 
nervous system) could be amplified through the interaction with other energy drink constitu-
ents (e.g. taurine) or ethanol in the alcoholic beverages consumed together with energy 
shots. Furthermore, these effects could also be amplified if energy shots are consumed in 
conjunction with physical exertion or sports activities. In this respect, certain potential risk 
groups such as consumers with cardiovascular disease and epileptics must be examined 
separately. This possibility and the existing information gaps would become more relevant in 
products that can lead to higher caffeine and taurine intake amounts than the consumption of 
energy drinks already entails, if the suggested intake levels are exceeded considerably. 
 
It should also be noted that consumers in night clubs may choose to increase their energy 
shot intake in an attempt to counteract fatigue after prolonged nightly outings or to deliber-
ately trigger a state of arousal. Since physical exertion also increases thirst, there is a risk 
that the manufacturer’s advice for intended use of the liquid energy shots is not adhered to. 
BfR is therefore of the opinion that it is likely that consumers will not always adhere to a use 
in accordance with the manufacturer’s advice for intended use. 
 
Sufficient data for the risk assessment of consumers with specific pathologies such as car-
diovascular diseases, epilepsy and possibly diabetes are not available. The BfR opinion that 
individuals with high blood pressure and cardiovascular diseases are recommended to re-
strain their consumption of energy drinks, also applies to caffeine and taurine intake through 
energy shots.  
 
For health risks of pregnant and breast-feeding women and children, refer to Chapter 3.4.1.1. 
 
3.4   Overall assessment and measures 
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According to the opinion of BfR it is likely that consumers will not always adhere to a use in 
accordance with the manufacturer’s advice. In light of these circumstances and potentially 
high caffeine intake levels resulting from considerably exceeded intakes with potentially ad-
verse effects, BfR assesses the above mentioned “energy shot” products as unsafe in terms 
of Article 14(1) of Regulation (EC) No 178/2002. In the case of “energy shot” products, such 
consumer behaviour (considerably excessive intake) cannot be avoided by manufacturer’s 
advice for intended use. BfR thus recommends that “energy shots” are prohibited from being 
placed on the market. 
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